STI Pharmaceuticals

STI Pharmaceuticals is a UK-based specialty pharmaceutical company that focuses on the development, registration, and supply of niche medicines for underserved therapeutic areas. The company is particularly recognized for its expertise in treatments for hyperhidrosis (excessive sweating) and sialorrhea (excessive drooling), with a core portfolio centered on various formulations of glycopyrronium bromide. Beyond dermatology and neurology, STI provides essential medicines for conditions such as phaeochromocytoma. In April 2021, the company was acquired by Essential Pharma, a group dedicated to ensuring the sustainable supply of low-volume, clinically well-established pharmaceutical products. Today, STI Pharmaceuticals operates as a subsidiary, leveraging its parent company's global reach to distribute its specialized therapeutic solutions.